(NYSE: LLY) Eli Lilly & Co's forecast annual revenue growth rate of 11.8% is forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 2.73%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 9.31%.
Eli Lilly & Co's revenue in 2023 is $29,239,500,000.On average, 5 Wall Street analysts forecast LLY's revenue for 2023 to be $29,238,640,595,037, with the lowest LLY revenue forecast at $28,476,831,663,000, and the highest LLY revenue forecast at $29,864,957,009,067. On average, 5 Wall Street analysts forecast LLY's revenue for 2024 to be $33,850,259,669,700, with the lowest LLY revenue forecast at $32,908,461,388,600, and the highest LLY revenue forecast at $34,508,256,915,272.
In 2025, LLY is forecast to generate $39,002,427,350,250 in revenue, with the lowest revenue forecast at $38,106,884,679,500 and the highest revenue forecast at $39,897,970,021,000.